In a filing, Conmed Corp revealed its Director Farkas Charles unloaded Company’s shares for reported $0.23 million on May 05 ’25. In the deal valued at $56.94 per share,4,000 shares were sold. As a result of this transaction, Farkas Charles now holds 16,346 shares worth roughly $0.85 million.
Then, Farkas Charles bought 4,000 shares, generating $227,768 in total proceeds.
Before that, Hartman Curt R bought 2,905 shares. Conmed Corp shares valued at $188,505 were divested by the Former Officer at a price of $64.89 per share.
Needham downgraded its Conmed Corp [CNMD] rating to a Hold from a a Buy in a research note published recently. A number of analysts have revised their coverage, including Stifel’s analysts, who decreased its forecast for the stock in late April from “a Buy” to “a Hold”. JP Morgan also remained covering CNMD and has decreased its forecast on February 06, 2025 with a “Neutral” recommendation from previously “an Overweight” rating. Needham maintained its rating on February 01, 2024. It rated CNMD as “a Buy”.
Price Performance Review of CNMD
On Tuesday, Conmed Corp [NYSE:CNMD] saw its stock fall -2.14% to $52.24. Over the last five days, the stock has lost -12.01%. Conmed Corp shares have fallen nearly -23.67% since the year began. Nevertheless, the stocks have fallen -28.28% over the past one year. While a 52-week high of $78.19 was reached on 02/05/25, a 52-week low of $46.00 was recorded on 04/21/25.
Levels Of Support And Resistance For CNMD Stock
The 24-hour chart illustrates a support level at 51.83, which if violated will result in even more drops to 51.42. On the upside, there is a resistance level at 52.89. A further resistance level may holdings at 53.53.
The most recent change occurred on May 22, 2023 when CL King began covering the stock and recommended ‘”a Buy”‘ rating along with a $140 price target.
